Invokana® (canagliflozin) and Invokamet® (canagliflozin and metformin) are prescription medications used to treat Type II Diabetes. Many Americans with Type II Diabetes depend on these medications to help them manage their blood sugar levels.
In 2015, the Food and Drug Administration (FDA) warned consumers using Invokana® and Invokamet® that these drugs may lead to a severe adverse reaction known as ketoacidosis, as well as an increased risk of bone fractures and loss of bone density.
If you or a loved one suffered injuries or were hospitalized for ketoacidosis after taking Invokana® or Invokamet®, you may be entitled to compensation. Your time to file a claim against the manufacturers of Invokana may be limited, so call the experienced North Carolina Drug Injury attorneys at Henson Fuerst right away.
What is Ketoacidosis?
Ketoacidosis is a dangerous medical condition where the body produces high levels of blood acids called “ketones.” This condition can require hospitalization, and could be fatal if left untreated.
Symptoms of ketoacidosis include:
- Excessive thirst
- Frequent urination
- Nausea and vomiting
- Abdominal pain
- Weakness or fatigue
- Shortness of breath
- Fruity-scented breath
The FDA identified three factors that may potentially trigger ketoacidosis in patients taking diabetes drugs such as Invokana® and Invokamet®:
- Major illness
- Reduced food and fluid intake
- Reduced insulin dose
FDA Warnings About Invokana® and Invokamet®
Invokana® and Invokamet® are members of a new class of drugs known as “SGLT2 inhibitors” that were approved by the FDA in 2013. When combined with diet and exercise, Invokana® and Invokamet® were marketed as a safe and effective method to help patients manage the symptoms of Type II Diabetes.
The FDA issued their first warning about the increased risk of ketoacidosis associated with Invokana® and Invokamet® in May of 2015. By September of 2015, the FDA had strengthened the warning labels on Invokana® and Invokamet® packaging. This expanded safety notice included warnings that Invokana® and Invokamet® were also linked to a loss of bone mineral density.
The September 2015 safety notice to consumers warned that:
- Canagliflozin, the active ingredient in both Invokana® and Invokamet®, has been proven to increase the risk of decreased bone mineral density in patients, especially in the hips and lower spine.
- Fractures and loss of bone density can begin as early as 12 weeks into treatment of this medication.
- The risk of bone fractures may be greater for post-menopausal women.
For older patients in particular, the loss of bone density can have a permanent and devastating impact on their lives. The risk of severe or even fatal injury from falls is already much greater for older Americans, and decreased bone density only heightens that risk.
Henson Fuerst is Here to Help
If you or a loved one suffered from ketoacidosis, broken bones, fractures, or any other serious injury after taking the diabetes medications Invokana® or Invokamet®, you may be entitled to compensation.
Call the experienced North Carolina Drug Injury attorneys at Henson Fuerst right away at (919) 781-1107 or fill out a free consultation form online. Our North Carolina Drug Injury attorneys will pursue your Drug Injury case with compassion and determination.
At Henson Fuerst, we have extensive experience standing up to major drug manufacturers on behalf of our clients. We will fight hard to recover the maximum compensation for your injuries. When you trust Henson Fuerst, you will never pay an attorney’s fee up front. In fact, you owe us nothing unless we recover for you.
Trust Henson Fuerst, Because Your Case Matters